Combined Optical and Infrared Imaging for Early Prediction of Erythema During Breast and Chestwall Radiotherapy
Launched by NOVA SCOTIA HEALTH AUTHORITY · Apr 24, 2020
Trial Information
Current as of June 29, 2025
Terminated
Keywords
ClinConnect Summary
There is currently no reliable tool to quantify and detect erythema of the skin during radiotherapy. This side-effect may lead to painful moist desquamation, and eventually permanent delayed side effects like telangiectasia. If such a tool would be available, several interventions could be staged, including (1) the use of steroid cream\], (2) the re-simulation and/or re-planning of patients to decrease the skin dose by spreading out the entrance of the beams, (3) adjusting or eliminating the use of bolus on the skin surface (which boosts superficial dose) or (4) the use of other treatment t...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • - All female patients referred for adjuvant radiotherapy following breast conserving surgery/mastectomy.
- Exclusion Criteria:
- • Patients with known skin issues (e.g. dermatomyositis, rosacea)
- • Patients with excessive risk of skin recurrence, including T4d
- • Patients with locally advanced breast cancer.
About Nova Scotia Health Authority
The Nova Scotia Health Authority (NSHA) is a leading healthcare organization dedicated to enhancing the health and well-being of individuals and communities across Nova Scotia, Canada. As the largest provider of health services in the province, NSHA is committed to advancing clinical research and innovation through rigorous clinical trials that aim to improve patient care and outcomes. With a focus on collaboration, NSHA engages healthcare professionals, researchers, and patients to address pressing health challenges and contribute to the global body of medical knowledge. By fostering a culture of evidence-based practice and continual improvement, NSHA plays a pivotal role in shaping the future of healthcare delivery in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halifax, Nova Scotia, Canada
Patients applied
Trial Officials
Michele Svatos, PhD
Principal Investigator
Dalhousie University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials